Position in KALV
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$7,071,769
New position
Shares Held
351,305
first reported quarter
Ownership
0.660%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#37
of 182 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SEB Asset Management AB holds $444,359,226 across 34 Biotechnology names. KALV ranks #22 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
140,951 | $62,940,259 | |
| 2 | INCY |
Incyte Corp
|
646,168 | $60,817,332 | |
| 3 | INSM |
INSMED Inc
|
165,576 | $27,074,987 | |
| 4 | PTGX |
Protagonist Therapeutics, Inc
|
232,416 | $24,496,646 | |
| 5 | IBRX |
ImmunityBio, Inc.
|
2,447,150 | $18,769,640 | |
| 6 | BNTX |
BioNTech SE
|
200,108 | $17,785,599 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
235,813 | $17,511,473 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
21,697 | $16,763,970 |
All Filings in KALV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,071,769 | 351,305 | Shares | Sole | 2026-05-07 | |
| No filing history on record for this holder in this stock. | ||||||